Skip to main content

Cytomegalovirus (CMV) Infection

3
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Kamada
KamadaIsrael - Negev
1 program
1
CytogamPhase 41 trial
Active Trials
NCT07009548Enrolling By Invitation45Est. Dec 2027
MSD
MSDIreland - Ballydine
1 program
1
Letermovir oral granulesPhase 21 trial
Active Trials
NCT03940586Completed65Est. Aug 2023
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Letermovir oral granulesPhase 2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
KamadaCytogam
MSDLetermovir oral granules

Clinical Trials (2)

Total enrollment: 110 patients across 2 trials

CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients

Start: Jun 2025Est. completion: Dec 202745 patients
Phase 4Enrolling By Invitation
NCT03940586MSDLetermovir oral granules

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

Start: Aug 2019Est. completion: Aug 202365 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.